Inspire Investing LLC Has $304,000 Position in Neurocrine Biosciences, Inc. $NBIX

Inspire Investing LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 45.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,750 shares of the company’s stock after buying an additional 861 shares during the quarter. Inspire Investing LLC’s holdings in Neurocrine Biosciences were worth $304,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in NBIX. Y Intercept Hong Kong Ltd bought a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $1,460,000. Golden State Wealth Management LLC raised its position in shares of Neurocrine Biosciences by 116.9% during the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after purchasing an additional 214 shares during the period. Fifth Third Bancorp raised its position in shares of Neurocrine Biosciences by 31.7% during the first quarter. Fifth Third Bancorp now owns 1,056 shares of the company’s stock worth $117,000 after purchasing an additional 254 shares during the period. Integrated Wealth Concepts LLC raised its position in Neurocrine Biosciences by 167.2% in the 1st quarter. Integrated Wealth Concepts LLC now owns 7,233 shares of the company’s stock valued at $800,000 after buying an additional 4,526 shares during the last quarter. Finally, Cetera Investment Advisers raised its position in Neurocrine Biosciences by 46.5% in the 4th quarter. Cetera Investment Advisers now owns 8,169 shares of the company’s stock valued at $1,115,000 after buying an additional 2,593 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Kevin Charles Gorman sold 106,322 shares of the firm’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the sale, the director directly owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jude Onyia sold 59,819 shares of the firm’s stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total value of $7,803,986.74. Following the sale, the insider directly owned 18,289 shares of the company’s stock, valued at $2,385,982.94. This represents a 76.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 186,960 shares of company stock valued at $23,955,553 in the last ninety days. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $145.66 on Friday. The stock has a market cap of $14.45 billion, a PE ratio of 43.09, a price-to-earnings-growth ratio of 1.03 and a beta of 0.28. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $154.61. The stock has a fifty day moving average of $135.03 and a 200 day moving average of $121.85.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The business had revenue of $687.50 million during the quarter, compared to analysts’ expectations of $653.09 million. During the same quarter in the prior year, the business posted $1.63 earnings per share. The business’s quarterly revenue was up 16.5% on a year-over-year basis. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Morgan Stanley lifted their price objective on Neurocrine Biosciences from $158.00 to $163.00 and gave the stock an “overweight” rating in a report on Friday, September 5th. UBS Group raised their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, July 9th. Stifel Nicolaus lifted their price target on Neurocrine Biosciences from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research report on Thursday, July 10th. They set a “buy” rating and a $182.00 price target for the company. Finally, JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $140.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $160.26.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.